BR112023000229A2 - Composto, composição farmacêutica, e, peptídeo - Google Patents

Composto, composição farmacêutica, e, peptídeo

Info

Publication number
BR112023000229A2
BR112023000229A2 BR112023000229A BR112023000229A BR112023000229A2 BR 112023000229 A2 BR112023000229 A2 BR 112023000229A2 BR 112023000229 A BR112023000229 A BR 112023000229A BR 112023000229 A BR112023000229 A BR 112023000229A BR 112023000229 A2 BR112023000229 A2 BR 112023000229A2
Authority
BR
Brazil
Prior art keywords
peptide
compound
pharmaceutical composition
coagonists
obesity
Prior art date
Application number
BR112023000229A
Other languages
English (en)
Inventor
J Knerr Patrick
Finan Brian
Liu Fa
Dimarchi Richard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112023000229A2 publication Critical patent/BR112023000229A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, E, PEPTÍDEO. São descritos coagonistas peptídicos dos receptores de GLP-1 e GIP humanos, seus derivados de ação prolongada e seu uso médico no tratamento e/ou prevenção de obesidade, diabetes e/ou doenças hepáticas.
BR112023000229A 2020-07-22 2021-07-22 Composto, composição farmacêutica, e, peptídeo BR112023000229A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055063P 2020-07-22 2020-07-22
EP20192415 2020-08-24
PCT/EP2021/070483 WO2022018185A1 (en) 2020-07-22 2021-07-22 Glp-1 and gip receptor co-agonists

Publications (1)

Publication Number Publication Date
BR112023000229A2 true BR112023000229A2 (pt) 2023-01-31

Family

ID=77179984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000229A BR112023000229A2 (pt) 2020-07-22 2021-07-22 Composto, composição farmacêutica, e, peptídeo

Country Status (14)

Country Link
US (1) US20230346961A1 (pt)
EP (1) EP4185606A1 (pt)
JP (1) JP2023534130A (pt)
KR (1) KR20230042019A (pt)
CN (1) CN116157414A (pt)
AU (1) AU2021313377A1 (pt)
BR (1) BR112023000229A2 (pt)
CA (1) CA3184723A1 (pt)
CL (1) CL2023000090A1 (pt)
CO (1) CO2023000125A2 (pt)
IL (1) IL299707A (pt)
MX (1) MX2023000403A (pt)
TW (1) TW202214679A (pt)
WO (1) WO2022018185A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402219B (zh) * 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
AR084558A1 (es) * 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
EP4331667A3 (en) * 2012-03-22 2024-05-08 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP2844669B1 (en) 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CA2910903A1 (en) * 2013-05-02 2014-11-06 Novo Nordisk A/S Oral dosing of glp-1 compounds
PE20151770A1 (es) 2013-05-28 2015-12-11 Takeda Pharmaceutical Compuesto peptidico
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
AU2014345569B2 (en) * 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
EP3827015A1 (en) 2018-07-23 2021-06-02 Eli Lilly and Company Gip/glp1 co-agonist compounds

Also Published As

Publication number Publication date
TW202214679A (zh) 2022-04-16
CA3184723A1 (en) 2022-01-27
CL2023000090A1 (es) 2023-07-07
CN116157414A (zh) 2023-05-23
AU2021313377A1 (en) 2023-02-02
IL299707A (en) 2023-03-01
EP4185606A1 (en) 2023-05-31
US20230346961A1 (en) 2023-11-02
CO2023000125A2 (es) 2023-04-17
KR20230042019A (ko) 2023-03-27
JP2023534130A (ja) 2023-08-08
WO2022018185A1 (en) 2022-01-27
MX2023000403A (es) 2023-02-02

Similar Documents

Publication Publication Date Title
BR112023000270A2 (pt) Composto, composição farmacêutica, e, peptídeo
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BR112023000229A2 (pt) Composto, composição farmacêutica, e, peptídeo
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
CY1110013T1 (el) Συνδυασμοι για θεραπεια πολλαπλου μυελωματος
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
NO20071875L (no) Bicykliske amider som kinaseinhibitorer
BR112022013150A2 (pt) Derivado da insulina
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
EA202190744A1 (ru) Слитый белок glp1-fc и его конъюгат
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
BRPI0409884A (pt) compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
PE20210123A1 (es) Compuesto de anillo de metillactama y uso farmaceutico del mismo
CL2023001556A1 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos
AR123039A1 (es) Coagonistas de los receptores de glp-1 y gip
BR0317292A (pt) Derivados de amida de ácido antranìlico e seu uso farmacêutico
DE60114844D1 (de) Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen